Literature DB >> 6529603

Further studies on the histamine metabolism in the M-2 adenocarcinoma.

A J Scolnick, M C Rubio, L L Colombo, R R Comolli, R A Caro.   

Abstract

Further studies of the histamine metabolism in the M-2 adenocarcinoma have shown that the tumor and the intestinal histidine decarboxylase should have similar conformations, since both enzymes exhibit superimposable curves of activity vs. pH as well as nearly identical 50% inhibitory concentrations for the specific inhibitor NSD-1015. It has also be found that the increase of the radioactivity uptake by the tumor nuclear fraction compared to the intestinal nuclear fraction after their incubation with 3H-histamine, may be due to qualitative differences between the nuclei, since endogenous contents of DNA and associated proteins were not significantly different. The specific binding of 3H-histamine to different purified DNAs demonstrated very dissimilar proportions of bound histamine, suggesting a possible interaction of histamine with DNA, similar to some of the proposed mechanisms for the modulation of the genomic expression of DNA by some polyamines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6529603

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  3 in total

1.  Increased histidine decarboxylase (HDC) activity in human colorectal cancer: results of a study on ten patients.

Authors:  M Garcia-Caballero; E Neugebauer; R Campos; I Nunez de Castro; C Vara-Thorbeck
Journal:  Agents Actions       Date:  1988-04

2.  ALA and ALA hexyl ester in free and liposomal formulations for the photosensitisation of tumour organ cultures.

Authors:  A Casas; C Perotti; M Saccoliti; P Sacca; H Fukuda; A M del C Batlle
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

3.  Tissue distribution and kinetics of endogenous porphyrins synthesized after topical application of ALA in different vehicles.

Authors:  A Casas; H Fukuda; A M Batlle
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.